Showing results (5151-5160 of 5,702) with videos related to
Sort By:
Pageof 571
The Oncologist|January 16, 2009
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosisMatthias Pinter, Wolfgang Sieghart, Ivo Graziadei, et al.The Oncologist|January 17, 2009
Commentary: Disclosure in oncology -- to whom does the truth belong?William A Wood, Mary S McCabe, Richard M GoldbergThe Oncologist|January 17, 2009
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor eraSwethajit Biswas, John Kelly, Tim EisenThe Oncologist|April 10, 2009
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLCNathan A Pennell, Thomas J LynchThe Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.The Oncologist|April 4, 2009
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancerSuresh S Ramalingam, Fadlo R KhuriThe Oncologist|April 4, 2009
Current treatment approaches for infants with malignant central nervous system tumorsLucie Lafay-Cousin, Douglas StrotherThe Oncologist|April 15, 2009
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapyElias Jabbour, Guillermo Garcia-Manero, Ali Taher, et al.The Oncologist|November 1, 2022
Clinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or CommitmentsJanice Kim, Robert Kester, Gideon BlumenthalThe Oncologist|October 1, 2022
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort StudyLei She, Xuan Gong, Lin Su, et al.Pageof 571